AxoGen (AXGN) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and mission

• Committed to making peripheral nerve repair a standard of care, aiming to restore function and improve quality of life for all patients.

• Four main clinical care pathways: extremities, breast reconstruction, oral/maxillofacial, and prostate.

• Strategic plan targets 15%-20% annual revenue growth from 2025–2028, with expansion into elective procedures and new markets like prostate.

• Emphasis on innovation, education, clinical partnerships, and societal endorsements to drive adoption.

• Clarity of purpose and measurable impact on patient outcomes are central to organizational culture.

Market opportunity and growth drivers

• Addressing a $5.6B US nerve care market with over 1.5 million annual injuries in key segments.

• Extremities remain the largest and most established business, while breast and oral/maxillofacial are high double-digit growth drivers.

• Direct-to-consumer advocacy is emphasized in breast reconstruction, with 70%-90% of the market seen as addressable.

• Commercial infrastructure and salesforce expansion support growth, with new hires productive in 6-9 months.

• Patient activation strategies and specialized sales teams drive adoption in breast resensation and prostate markets.

Product innovation and clinical evidence

• Avance Nerve Graft is the first FDA-approved biologic for nerve discontinuity repair, preserving native nerve architecture and supporting axonal regeneration.

• Comprehensive portfolio includes Avance, Axoguard, and Avive+ for various nerve repair needs.

• Completion of the Biologics License Application (BLA) enables focus on a single quality system and further manufacturing investments.

• Ongoing and planned clinical studies aim to generate Level 1 evidence and support standard of care adoption, starting with breast and mixed/motor nerve applications.

• Ongoing R&D includes next-generation Avance, improved grafting techniques, and protection technologies.